Exclusive: Houston entrepreneurial hub set to acquire local fintech startup

growth stage

The Cannon has announced plans to acquire Houston-based crowdfunding startup LetsLaunch. Courtesy of Quy Tran/The Cannon

The Cannon, a Houston startup development organization with a network of coworking hubs, has announced its plans to acquire a Houston fintech startup.

LetsLaunch, an online investment platform that allows for smaller investments from non-accredited investors, has been connected with The Cannon in the past, and the two entities have even had a partnership arrangement. Now, The Cannon has plans to acquire LetsLaunch in order to provide Cannon member companies with the fundraising option.

"The Cannon and LetsLaunch have a shared vision for enabling and optimizing the innovation ecosystem," says Jon Lambert, CEO of The Cannon, in a news release. "LetsLaunch has passionately developed a technology platform that will deliver significant value to the entrepreneurial community by bringing together start-ups and investors of all kinds. By integrating the LetsLaunch platform into The Cannon's digital offerings, we will enhance the fundraising and strategic connection value we offer to our innovation community."

Lambert says the opportunity to provide The Cannon's members this opportunity to fundraise comes at an important time.

"Fundraising in the COVID-19/Post COVID-19 era is, and is likely to remain, a bit of an unknown," he continues in the release. "Adding another viable funding channel for the startups in our community who are ready for investment will be a valued benefit for our members and will provide us exposure to a whole new group of entrepreneurial investors."

The terms of the deal haven't been disclosed, but it is expected to close in June 2020. The transaction remains subject to customary closing conditions and approvals.

"We built LetsLaunch to provide broad segments of the population with a mechanism to invest in startups, while giving startups another source of capital," says Nick Carnrite, who co-founded LetsLaunch in 2018, in the release. "Crowdfunding will always remain at LetsLaunch's core, but it also became clear we had a role to play in connecting the innovation community, including startups, investors, advisors, mentors and service providers, based on their location, interests and preferences."

According to the release, the acquisition falls in line with both companies' missions to help develop an ecosystem of resources for startups.

"[LetsLaunch's] vision is completely complementary to The Cannon's goal to develop a tightly integrated innovation ecosystem," adds Brian Coyle, co-founder of LetsLaunch. "There is no better time to work together to help support private businesses."

Houston-based Sensorfield was selected to participate in a Chevron Technology Ventures program. Courtesy of Sensorfield

Houston biotech company closes $120M Series B, Chevron taps local startup for program, and more innovation news

Short stories

Big things are happening in Houston — from a $120 million close to the U.S. Department of Energy picking a Houston-area company for nuclear energy research. Here are the highlights of Houston innovation news you might have missed.

Need more news rounded up for you? Subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

Houston immunotherapy company raises $120 million in funding

Getty Images

AlloVir, a Houston biotech company founded at Baylor's Center for Cell and Gene Therapy, has closed a $120 million Series B round that was led by Fidelity Management and Research Company. Other contributors included Gilead Sciences, F2 Ventures, Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners Co-investment Fund, LLC.

The company is currently in clinical trials for its immunotherapy technology and also announced it is joining the ElevateBio — a Boston-based organization that combines a group of cell and gene therapy companies — portfolio.

"We are excited to now be building AlloVir as an ElevateBio portfolio company," says Ann Leen, AlloVir co-founder, CSO, and Professor of Pediatrics at Baylor College of Medicine, in a release. "This partnership provides AlloVir with fully integrated bench-to-bedside capabilities to accelerate the development and commercialization of our allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies."

Allovir, which until recently was known as ViraCyte, was founded in 2013.

Chevron taps Houston startup for pilot program

Photo courtesy of Sensorfield

Houston-based Sensorfield LLC, which has developed a suite of wireless sensors for industrial monitoring, has announced that it has been selected for Chevron Technology Ventures' Catalyst Program.

"Technology has finally reached the point where embedded solar-powered, plug-and-play industrial wireless sensors are possible at a low cost,'' says Sensorfield founder and CEO, Strode Pennebaker, in a release. "Our exciting new association with Chevron is a major step in our goal to bring cost-effective, high-quality intelligent remote monitoring to asset owners at any scale."

Department of Energy selects a Houston-area company for funding

Courtesy of the DOE

U.S. Department of Energy is awarding $10.6 million for nuclear technology development across three projects in three states — one is in Wadsworth, Texas, about 80 miles outside of Houston.

The company, STP Nuclear Operating Company, will receive $1.18 million in DOE funding, according to a release, to develop and implement advanced fire probabilistic risk assessment — or PRA — modeling techniques.

"These projects are important because they will help the U.S. continue to develop advanced reactors and technologies to support nuclear energy as a safe, zero-emissions baseload energy source," says Carrie Edwards, senior adviser for the Office of Nuclear Energy at the DOE, in an email.

Rice University launches executive education program in The Woodlands

Rice University's Jones Graduate School of Business — in partnership with The Woodlands Area Economic Development Partnership — has created The Leadership Accelerator. It's the first time Rice has brought an open enrollment program to the area.

The program will take place from October 7 to 10 program at the former Chicago Bridge & Iron Co. office buildings in Hughes Landing (2103 Research Forest Drive). Professor Brent Smith will lead the course .

The four-day course will build upon established managers' careers and give them an opportunity to study best practices for creating a more productive organization.

Carnrite Ventures expands to Austin

Courtesy of Nick Carnrite

Houston-based The Carnrite Group's investment arm, Carnrite Ventures, has agreed to invest with Seraph Group. The partnership allows for the Houston VC group to expand its portfolio to Austin, as that's where Seraph's last fund focused on.

"Austin's venture capital funds have moved up-market to series B and C funding rounds, which has created a need for more capital in earlier stages and provides us with an opportunity," says Nick Carnrite, Managing Director of The Carnrite Group and Carnrite Ventures, in a release.

Houston scientifically-designed athleticwear startup launches men's line

Courtesy of Accel Lifestyle

Accel Lifestyle, a Houston-based athletic clothing line made with its patented anti-stink material, has launched its menswear line.

"After three years in the making, I'm beyond thrilled to announce that Accel Lifestyle Men's Collection has launched," says Megan Eddings, founder of Accel. "We are focusing on shirts (t-shirts and tanks), and we are planning to launch the women's collection late next month."

The products are made in America and all ethically sourced — even the product's shipping material, as it has zero plastic involved.

From debt and equity funds to crowdfunding and angel investment, here's what you need to know about the fundraising world from an expert who's in it. Getty Images

Houston entrepreneur gives his advice on navigating the evolving fundraising process

know before you grow

New businesses face many challenges when getting started, but perhaps none are as challenging and intimidating as how to secure the funding needed to start and grow your business.

Funding options have evolved considerably over the past several years, providing business owners with more choices than ever to fund their business. Founders should not just think about selecting one option but how to combine multiple options into a funding strategy that best suits their business needs.

Over 600,000 new businesses are started in the United States each year, and even with more fundraising options, we are increasingly seeing businesses struggle to get funded, so businesses need to be smart about putting together a funding strategy.

The traditional way to fund a business
With that piece of advice out of the way, there are two primary categories of capital: debt and equity. For your business, debt options may include personal loans, business loans, asset-based loans, revenue participation notes and factoring (where you sell your receivables at a discount in order to collect cash now).

Debt is great as it means you're not giving away equity, but, at the same time, the loan must eventually be paid back (with interest) and some businesses such as technology start-ups may not generate the cash flow needed to make this happen from day one. Loans can also be difficult to access or may require the business owner to put up a personal guarantee, although there are organizations that facilitate this such as Small Business Association. If this is the best route for your business, take the time to find the right lending organization.

Equity options include common stock and preferred stock, as well as convertible note instruments that are initially treated as debt but "convert" to equity at a future financing event. Unlike traditional equity, convertible note instruments allow you to delay establishing a valuation for your business, which can be challenging for startups. SAFE (Simple Agreement for Future Equity) and KISS (Keep It Simple Securities) Notes are emerging securities which are less frequent but are seen as more Founder friendly and are similar in some ways to convertible notes.

There are a lot of business owners that are cautious of giving away equity (and rightly so) but with the right advice on structuring securities and valuation, this can be a great source of capital, as well as knowledge and support if you find the right investors and partners.

Sources of funding for both debt and equity include friends, family, banks, angel investors, venture capital, private equity, and organizations such as the Small Business Association. The accessibility of these various options will depend on the maturity of your business, your industry and the needs of your company. Often, early-stage companies may source "seed" funding from friends, family, and angel investors, while venture capital, private equity, and debt become increasingly accessible at later stages as revenues grow.

How is funding changing?
Options for funding a business and investing have evolved considerably in recent years. Crowdsourcing, which can be defined as the process of obtaining needed services, ideas, or content by soliciting contributions from a large group of people, and especially from an online community, has taken the world by storm. Companies such as Uber, AirBnb, and Grubhub all leverage "the crowd" to provide a service.

Crowdsourcing has made its way to finance as well, where companies such as GoFundMe and KickStarter have provided new tools to fund charitable causes and projects. The Jumpstart Our Business Startups Act (JOBS Act) of 2012 set in motion a series of regulatory changes that allowed anybody (not just high wealth individuals) to invest in private businesses and provided crowdfunding as an option to raise capital for small businesses.

Online crowdfunding portals such as LetsLaunch, SeedInvest, and WeFunder offer both debt and equity options for investors to invest in your business. Not only can this be a great way to build up a loyal customer base, test your product and get some great marketing exposure but it can also be a great way to supplement the traditional funding strategies mentioned above.

However you choose to fund your business, take the time to work through the options (both traditional and emerging) and find the right option or combination of options to meet your business needs.

------

Nick Carnrite is managing director of Carnrite Group and co-founder and CEO of LetsLaunch.

LetsLaunch, a new Houston-based fundraising platform, helps companies of all sizes get funding from any type of investor. Courtesy of LetsLaunch

Houston fundraising platform launches for the next generation of investors

Future funders

Millennials are expected to exceed the Baby Boomer generation for the United States' largest living adult generation this year, and this massive population of people have a completely different approach to investing.

Nick Carnrite saw that Millennials were to a point where they had extra income, but when he looked at the statistics, he noticed they aren't buying houses for the most part and were turned off of the stock market. There was a huge amount of stranded capital, and he wanted to figure out how to get that invested into businesses.

"The younger generation isn't interested in typical investing, but they are absolutely interested in supporting their community and the businesses in it, especially if the investment lets them experience the business and come along for the ride if it works," Carnrite, who is the co-founder and CEO of LetsLaunch, says.

Houston-based LetsLaunch is a new investment platform that launched December 28, though has been in the works since January 2018. The site works, in many ways, like a crowdfunding site, only investors receive equity. Due to regulations, investment campaigns max out at around a million dollars.

In the past, entrepreneurs have had to seek out major investors through venture capitalists or large funds, since taking smaller investments is tedious and almost more trouble than its worth. However, LetsLaunch provides a platform where smaller investments are streamlined and encouraged.

"Our goal in all of this is just to take a complicated process and make it simple, the same way Turbotax takes something awful like taxes and makes it simple, we are trying to do that with investing," Carnrite says.

Investors don't have to be accredited or invest a certain amount of money — something that for so long has hindered startups' ability to raise money.

"For whatever reason, we've decided to alienate about 95 percent of Americans as far as being able to invest in private businesses," Carnrite says. "Finally, we're at the point where all of that capital that was stranded and not allowed in private companies is being funneled into that cause."

According to Carnrite and his associate, Rhian Davies, who is the company's director of business operations, the mission is to educate and simplify the investing process.

"For us, one of the things we're working on with other organizations is putting together a next-gen investor series, where we are teaching the next generation of investors how to invest and give them a platform to do it," Davies says.

Much like in a normal investment process, the companies provide a pitch deck for potential investors that outlines the business plan and scope of the company. The company simply creates an account and uses the website to develop those materials.

"We standardize that process, so from a user standpoint, everything looks fairly similar on our site and it's a pretty tried and true template," Carnrite says.

While LetsLaunch does its due diligence making sure the business is legitimate and makes sure the pitch deck is sufficient, the investors take it from there.

Since ease of access to funds is the top priority for LetsLaunch, the investment platform has a much lower fee for companies. While some crowdfunding platforms take 10 to 12 percent, LetsLaunch's fee is around 3 percent.

"We really want it to be simple and affordable to businesses and for investors as well," Davies says. "We maintain a much lower fee than other crowdfunding sites."

LetsLaunch will continue to fine tune its existing features on the site, while also adding more tools for businesses, including an iOS mobile app, which Carnirite says will be ready this year. In addition to fundraising tools, Carnrite wants to help their businesses after the campaigns with software that streamlines investor relations and reminds business owners of important deadlines.

"We want to evolve into a website that not only helps you raise capital for a company, but that also helps you run that company after your raise, Carnrite says."

While Houston is home base for the company, the team expects to expand to other markets where fundraising is hard, like Denver, Atlanta, Dallas, and more. Strategic partnerships are another opportunity for LetsLaunch, and the company expects to finalize some of those moving forward.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings